Literature DB >> 28379801

Transplantation for Myeloma - Now or Later?

Charles A Schiffer1, Jeffrey A Zonder1.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28379801      PMCID： PMC6860019          DOI： 10.1056/NEJMe1700453

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  10 in total

1.  Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial.

Authors:  Philippe Moreau; Thierry Facon; Michel Attal; Cyrille Hulin; Mauricette Michallet; Frédéric Maloisel; Jean-Jacques Sotto; François Guilhot; Gérald Marit; Chantal Doyen; Jérôme Jaubert; Jean-Gabriel Fuzibet; Sylvie François; Lotfi Benboubker; Matthieu Monconduit; Laurent Voillat; Margaret Macro; Christian Berthou; Véronique Dorvaux; Bernard Pignon; Bernard Rio; Thomas Matthes; Philippe Casassus; Denis Caillot; Norbert Najman; Bernard Grosbois; Régis Bataille; Jean-Luc Harousseau
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

2.  High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial.

Authors:  J P Fermand; P Ravaud; S Chevret; M Divine; V Leblond; C Belanger; M Macro; E Pertuiset; F Dreyfus; X Mariette; C Boccacio; J C Brouet
Journal:  Blood       Date:  1998-11-01       Impact factor: 22.113

3.  Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.

Authors:  Brian G M Durie; Antje Hoering; Muneer H Abidi; S Vincent Rajkumar; Joshua Epstein; Stephen P Kahanic; Mohan Thakuri; Frederic Reu; Christopher M Reynolds; Rachael Sexton; Robert Z Orlowski; Bart Barlogie; Angela Dispenzieri
Journal:  Lancet       Date:  2016-12-23       Impact factor: 79.321

4.  Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.

Authors:  Michel Attal; Valerie Lauwers-Cances; Cyrille Hulin; Xavier Leleu; Denis Caillot; Martine Escoffre; Bertrand Arnulf; Margaret Macro; Karim Belhadj; Laurent Garderet; Murielle Roussel; Catherine Payen; Claire Mathiot; Jean P Fermand; Nathalie Meuleman; Sandrine Rollet; Michelle E Maglio; Andrea A Zeytoonjian; Edie A Weller; Nikhil Munshi; Kenneth C Anderson; Paul G Richardson; Thierry Facon; Hervé Avet-Loiseau; Jean-Luc Harousseau; Philippe Moreau
Journal:  N Engl J Med       Date:  2017-04-06       Impact factor: 91.245

5.  High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

Authors:  J Anthony Child; Gareth J Morgan; Faith E Davies; Roger G Owen; Susan E Bell; Kim Hawkins; Julia Brown; Mark T Drayson; Peter J Selby
Journal:  N Engl J Med       Date:  2003-05-08       Impact factor: 91.245

6.  A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.

Authors:  M Attal; J L Harousseau; A M Stoppa; J J Sotto; J G Fuzibet; J F Rossi; P Casassus; H Maisonneuve; T Facon; N Ifrah; C Payen; R Bataille
Journal:  N Engl J Med       Date:  1996-07-11       Impact factor: 91.245

7.  High-dose melphalan with autologous bone marrow transplantation for multiple myeloma.

Authors:  B Barlogie; R Hall; A Zander; K Dicke; R Alexanian
Journal:  Blood       Date:  1986-05       Impact factor: 22.113

8.  Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support.

Authors:  S Jagannath; D H Vesole; L Glenn; J Crowley; B Barlogie
Journal:  Blood       Date:  1992-10-01       Impact factor: 22.113

9.  Single versus double autologous stem-cell transplantation for multiple myeloma.

Authors:  Michel Attal; Jean-Luc Harousseau; Thierry Facon; François Guilhot; Chantal Doyen; Jean-Gabriel Fuzibet; Mathieu Monconduit; Cyrille Hulin; Denis Caillot; Reda Bouabdallah; Laurent Voillat; Jean-Jacques Sotto; Bernard Grosbois; Regis Bataille
Journal:  N Engl J Med       Date:  2003-12-25       Impact factor: 91.245

10.  Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.

Authors:  S K Kumar; A Dispenzieri; M Q Lacy; M A Gertz; F K Buadi; S Pandey; P Kapoor; D Dingli; S R Hayman; N Leung; J Lust; A McCurdy; S J Russell; S R Zeldenrust; R A Kyle; S V Rajkumar
Journal:  Leukemia       Date:  2013-10-25       Impact factor: 11.528
  10 in total
  2 in total

Review 1.  Novel Agents in Multiple Myeloma.

Authors:  Raphaël Szalat; Nikhil C Munshi
Journal:  Cancer J       Date:  2019 Jan/Feb       Impact factor: 3.360

2.  Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time.

Authors:  S K Kumar; A Dispenzieri; R Fraser; F Mingwei; G Akpek; R Cornell; M Kharfan-Dabaja; C Freytes; S Hashmi; G Hildebrandt; L Holmberg; R Kyle; H Lazarus; C Lee; J Mikhael; T Nishihori; J Tay; S Usmani; D Vesole; R Vij; B Wirk; A Krishnan; C Gasparetto; T Mark; Y Nieto; P Hari; A D'Souza
Journal:  Leukemia       Date:  2017-11-16       Impact factor: 11.528
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.